Gilead expands oncology business with Pionyr deal

25-06-2020

Gilead expands oncology business with Pionyr deal

Sundry Photography / Shutterstock.com

Gilead Sciences has begun a potential takeover of Pionyr Immunotherapeutics after it agreed to pay $275 million for a 49.9% equity stake in the cancer research company.


Gilead, Pionyr, immunotherapeutics, immuno-oncology, cancer, antivirals, Daniel O’Day, buyout, FDA

LSIPR